Repligen (RGEN) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2023
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Securities Act File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		55,756,322

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 603,656	$ 523,458
Marketable securities held to maturity	0	100,299
Accounts receivable, net of reserves of $1,571 and $1,365 at June 30, 2023 and December 31, 2022, respectively	120,304	116,247
Inventories, net	240,869	238,277
Prepaid expenses and other current assets	33,754	19,837
Total current assets	998,583	998,118
Property, plant and equipment, net	202,564	190,673
Intangible assets, net	351,704	353,676
Goodwill	870,688	855,513
Deferred tax assets	1,756	840
Operating lease right of use assets	122,044	125,023
Other noncurrent assets	1,664	815
Total noncurrent assets	1,550,420	1,526,540
Total assets	2,549,003	2,524,658
Current liabilities:
Accounts payable	23,787	27,554
Operating lease liability	2,889	6,957
Current contingent consideration	16,363	13,950
Accrued liabilities	45,023	71,120
Convertible Senior Notes, net	285,521	284,615
Total current liabilities	373,583	404,196
Deferred tax liabilities	21,897	23,000
Noncurrent operating lease liability	134,438	131,389
Noncurrent contingent consideration	44,277	51,559
Other noncurrent liabilities	3,882	3,814
Total noncurrent liabilities	204,494	209,762
Total liabilities	578,077	613,958
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,744,896 shares at June 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	557	556
Additional paid-in capital	1,561,393	1,547,266
Accumulated other comprehensive loss	(37,189)	(34,394)
Accumulated earnings	446,165	397,272
Total stockholders' equity	1,970,926	1,910,700
Total liabilities and stockholders' equity	$ 2,549,003	$ 2,524,658

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts receivable, reserve for doubtful accounts	$ 1,571	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	55,744,896	55,557,698
Common stock, shares outstanding	55,744,896	55,557,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Revenue	$ 159,169	$ 207,633	$ 341,829	$ 414,033
Costs and operating expenses:
Cost of product revenue	79,307	86,260	161,152	168,616
Research and development	9,706	10,440	21,860	22,595
Selling, general and administrative	48,966	54,649	105,136	108,949
Contingent consideration	1,791	(6,884)	3,026	(9,295)
Total costs and operating expenses	139,770	144,465	291,174	290,865
Income from operations	19,399	63,168	50,655	123,168
Other income (expenses):
Investment income	5,964	708	11,450	785
Interest expense	(274)	(271)	(544)	(563)
Amortization of debt issuance costs	(457)	(453)	(914)	(905)
Other expenses	528	(3,396)	605	(3,798)
Other income (expenses), net	5,761	(3,412)	10,597	(4,481)
Income before income taxes	25,160	59,756	61,252	118,687
Income tax provision	5,096	9,895	12,359	21,862
Net income	$ 20,064	$ 49,861	$ 48,893	$ 96,825
Earnings per share:
Basic	$ 0.36	$ 0.9	$ 0.88	$ 1.75
Diluted (Note 11)	$ 0.35	$ 0.88	$ 0.86	$ 1.68
Weighted average common shares outstanding:
Basic	55,705	55,444	55,648	55,399
Diluted (Note 11)	56,858	56,721	56,932	57,842
Net Income (Loss)	$ 20,064	$ 49,861	$ 48,893	$ 96,825
Other comprehensive income (loss):
Foreign currency translation adjustment	(6,068)	(15,517)	(2,795)	(20,205)
Comprehensive income	13,996	34,344	46,098	76,620
Products
Revenue:
Revenue	159,133	207,597	341,754	413,960
Royalty and other revenue
Revenue:
Revenue	$ 36	$ 36	$ 75	$ 73

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Translation adjustment	$ (20,205,000)			$ (20,205,000)
Balance at Dec. 31, 2021	1,750,067,000	$ 553,000	$ 1,572,340,000	(16,886,000)	$ 194,060,000
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net Income (Loss)	96,825,000				96,825,000
Issuance of common stock for debt conversion	(5,000)	$ 0	(5,000)
Issuance of common stock for debt conversion (in shares)		12
Exercise of stock options and vesting of stock units	463,000	$ 3,000	460,000
Exercise of stock options and vesting of stock units (in shares)		222,727
Tax withholding on vesting of restricted stock units	(14,759,000)	$ (1,000)	(14,758,000)
Tax withholding on vesting of restricted stock units (in shares)		(78,278)
Stock-based compensation expense	14,900,000		14,900,000
Other	(105,000)		(105,000)
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Jun. 30, 2022		55,465,918
Translation adjustment	(15,517,000)			(15,517,000)
Balance at Mar. 31, 2022	1,766,401,000	$ 554,000	1,529,144,000	(21,574,000)	258,277,000
Beginning Balance (in shares) at Mar. 31, 2022		55,429,046
Net Income (Loss)	49,861,000				49,861,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		4
Exercise of stock options and vesting of stock units	166,000	$ 1,000	166,000
Exercise of stock options and vesting of stock units (in shares)		51,737
Tax withholding on vesting of restricted stock units	(2,448,000)	$ 0	(2,448,000)
Tax withholding on vesting of restricted stock units (in shares)		(14,869)
Stock-based compensation expense	6,985,000		6,985,000
Other	(82,000)		(82,000)
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Jun. 30, 2022		55,465,918
Translation adjustment	(2,795,000)			(2,795,000)
Balance at Dec. 31, 2022	1,910,700,000	$ 556,000	1,547,266,000	(34,394,000)	397,272,000
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net Income (Loss)	48,893,000				48,893,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	62,000	$ 2,000	60,000
Exercise of stock options and vesting of stock units (in shares)		176,394
Tax withholding on vesting of restricted stock units	(11,140,000)	$ (1,000)	(11,139,000)
Tax withholding on vesting of restricted stock units (in shares)		(63,238)
Issuance of commons stock pursuant to the acquisition	5,243,000	$ 0	5,243,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000	$ 0	7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		42,621
Stock-based compensation expense	12,737,000		12,737,000
Balance at Jun. 30, 2023	1,970,926,000	$ 557,000	1,561,393,000	(37,189,000)	446,165,000
Ending Balance (in shares) at Jun. 30, 2023		55,744,896
Translation adjustment	(6,068,000)			(6,068,000)
Balance at Mar. 31, 2023	1,940,492,000	$ 556,000	1,544,956,000	(31,121,000)	426,101,000
Beginning Balance (in shares) at Mar. 31, 2023		55,644,301
Net Income (Loss)	20,064,000				20,064,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	33,000	$ 1,000	32,000
Exercise of stock options and vesting of stock units (in shares)		36,184
Tax withholding on vesting of restricted stock units	(1,547,000)	$ 0	(1,547,000)
Tax withholding on vesting of restricted stock units (in shares)		(9,631)
Issuance of commons stock pursuant to the acquisition	5,243,000	$ 0	5,243,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000	$ 0	7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		42,621
Stock-based compensation expense	5,483,000		5,483,000
Balance at Jun. 30, 2023	$ 1,970,926,000	$ 557,000	$ 1,561,393,000	$ (37,189,000)	$ 446,165,000
Ending Balance (in shares) at Jun. 30, 2023		55,744,896

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 48,893	$ 96,825
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	31,237	23,933
Amortization of debt issuance costs	914	905
Stock-based compensation	12,737	14,900
Deferred income taxes, net	(2,196)	738
Contingent consideration	3,026	(9,295)
Noncash interest income	(2,023)	0
Other	574	276
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(4,606)	(8,433)
Inventories	(2,508)	(58,106)
Prepaid expenses and other assets	(11,530)	2,402
Operating lease right of use assets	6,487	(21,457)
Other assets	(888)	(406)
Accounts payable	(3,871)	6,322
Accrued expenses	(26,234)	(4,014)
Operating lease Liabilities	(4,544)	23,852
Long-term liabilities	154	392
Total cash provided by operating activities	45,622	68,834
Cash flows from investing activities:
Acquisitions, net of cash acquired	(28,099)	0
Proceeds from maturity of marketable securities held to maturity	102,323	0
Additions to capitalized software costs	(2,075)	(1,875)
Purchases of property, plant and equipment	(16,749)	(52,576)
Other investing activities	0	17
Total cash provided by (used in) investing activities	55,400	(54,434)
Cash flows from financing activities:
Proceeds from exercise of stock options	62	463
Payment of tax withholding obligation on vesting of restricted stock	(11,140)	(14,759)
Repayment of Convertible Senior Notes	(9)	(18)
Payment of earnout consideration	(7,298)	0
Proceeds from issuance of common stock, net	(3)	0
Total cash used in financing activities	(18,388)	(14,314)
Effect of exchange rate changes on cash and cash equivalents	(2,436)	(7,388)
Net increase (decrease) in cash and cash equivalents	80,198	(7,302)
Cash, cash equivalents and restricted cash, beginning of period	523,458	603,814
Cash and cash equivalents, end of period	603,656	596,512
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	831	21,739
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	5,243	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of contingent consideration earnouts related to acquisition	$ 7,229	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	6 Months Ended
	Jun. 30, 2023 shares
FlexBiosys, Inc.
Shares of common stock issued for acquisition	31,415
Avitide, Inc.
Shares of common stock issued for acquisition	42,621

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 20,064	$ 49,861	$ 48,893	$ 96,825

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	None of the Company's directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, modified, or terminated a Rule 10(b)5-1 trading arrangement during the Company's fiscal quarter ended June 30, 2023.
Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Ltd., ARTeSYN Biosolutions Ireland Limited and its subsidiaries ("ARTeSYN"), Polymem S.A. (“Polymem”), Avitide LLC ("Avitide"), Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex"), Repligen Singapore Pte. Ltd., Repligen UK Limited and FlexBiosys, Inc. ("FlexBiosys"). All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes, which the Company adopted effective January 1, 2022 as required by Accounting Standards Update No. ("ASU" or "ASUs") 2020-06 and discussed in Note 6, "Convertible Senior Notes," to these condensed consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the three and six months ended June 30, 2023 and 2022 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s condensed consolidated financial statements. As of June 30, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Disclosure Text Block [Abstract]
Fair Value Measurements	2. Fair Value Measurements The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 - Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Cash, Cash Equivalents and Marketable Securities Held to Maturity The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of June 30, 2023 and December 31, 2022 (amounts in thousands): As of June 30, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 603,656 $ — $ — $ 603,656 Total cash and cash equivalents $ 603,656 $ — $ — $ 603,656 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills - short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781 During the fourth quarter of 2022, the Company purchased $ 100.0 million of 6-month U.S. treasury bills with the positive intent and ability to hold them until maturity. Therefore, the Company classified this investment as held to maturity and stated it at amortized cost on the condensed consolidated balance sheet. These U.S. treasury bills matured in June 2023. The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 is summarized below: December 31, 2022 Amortized Estimated Maturity of one year or less $ 100,299 $ 100,323 Total $ 100,299 $ 100,323 Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2023 and December 31, 2022 (amounts in thousands): As of June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 433,966 $ — $ — $ 433,966 Liabilities: Short-term contingent consideration $ — $ — $ 16,363 $ 16,363 Long-term contingent consideration $ — $ — $ 44,277 $ 44,277 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559 Contingent Consideration – Earnouts As of June 30, 2023 , the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with the completed acquisitions of Avitide in September 2021 and FlexBiosys in April 2023, was $ 125.0 million over a three-year earnout period and $ 42.0 million over a two-year earnout period, respectively. Refer to Note 4, "Acquisitions" included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K and Note 3, "Acquisition of FlexBiosys, Inc.," to this report for additional information on the contingent consideration earnouts. During 2023, a change in market inputs used to calculate the discount rate resulted in an increase in amounts reported as of June 30, 2023 . A reconciliation of the change in the fair value of contingent consideration - earnouts is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Acquisition date fair value of contingent consideration earnout 6,632 Payment of contingent consideration earnout ( 14,527 ) Decrease in fair value of contingent consideration earnouts 3,026 Balance at June 30, 2023 $ 60,640 The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023, 2024 and 2025 contingent consideration obligations for Avitide and FlexBiosys include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 19,175 Monte Carlo Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Volatility 22.5 %- 24.6 % 23.6 % Revenue and Volume- $ 35,960 Monte Carlo Revenue & Volume 5.7 %- 9.3 % 7.5 % Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Probability of 100 % 100 % Manufacturing line expansions $ 5,505 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. Fair Value Measured on a Nonrecurring Basis During the three and six months ended June 30, 2023 , there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis.

Acquisition of FlexBiosys, Inc

Acquisition of FlexBiosys, Inc	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition of FlexBiosys, Inc.	3. Acquisition of FlexBiosys, Inc. On April 17, 2023 , the Company completed its acquisition of all of the outstanding equity interests in FlexBiosys, Inc. ("FlexBiosys"), pursuant to an Equity Purchase Agreement ("EPA") with FlexBiosys, TSAP Holdings Inc. ("NJ Seller"), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the "Sellers"), and Stanley Tarry, in his capacity as the representative of the Sellers (the "FlexBiosys Acquisition"). FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings. Consideration transferred The FlexBiosys Acquisition was accounted for as a purchase of a business under ASC 805, "Business Combinations," and the Company engaged a third-party valuation firm to assist with the valuation of FlexBiosys. Under the terms of the EPA, all outstanding equity interests of FlexBiosys were acquired for consideration with a value totaling $ 41.1 million. The FlexBiosys Acquisition was funded through payment of $ 29.0 million in cash, which includes $ 6.3 million deposited in escrow for future payments, the issuance of 31,415 unregistered shares of the Company's common stock totaling $ 5.4 million and contingent consideration with fair value of approximately $ 6.6 million. Under the acquisition method of accounting, the assets acquired and liabilities assumed of FlexBiosys were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is estimated to be $ 14.1 million, the fair value of the intangible assets acquired is estimated to be $ 12.6 million and the residual goodwill is estimated to be $ 14.4 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 0.4 million of transaction and integration costs associated with the FlexBiosys Acquisition from the date of acquisition to June 30, 2023. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the three and six months ended June 30, 2023. Fair Value of Net Assets Acquired The preliminary allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date. As of June 30, 2023, the purchase accounting for this acquisition had not been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. Besides tax implications of the purchase price allocation, the final allocation may result in changes to the consideration paid related to working capital adjustments as well as changes to other assets and liabilities. The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 9,530 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,355 Other long-term assets 2,514 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Operating lease liability, long-term ( 3,498 ) Fair value of net assets acquired $ 41,064 Acquired Goodwill The goodwill of $ 14.4 million represents future economic benefits expected to arise from anticipated synergies from the integration of FlexBiosys into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the FlexBiosys Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Revenue Recognition	4. Revenue Recognition Disaggregation of Revenue Revenues for the three and six months ended June 30, 2023 and 2022 were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Product revenue $ 159,133 $ 207,597 $ 341,754 $ 413,960 Royalty and other income 36 36 75 73 Total revenue $ 159,169 $ 207,633 $ 341,829 $ 414,033 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because substantially all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, regulatory, economic and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenue is generated from a small number of customers; therefore, economic factors specific to these customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 13, “Segment Reporting,” included in this report. For more information regarding our product revenue, see Note 6, “Revenue Recognition” included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2023 (amounts in thousands): June 30, December 31, 2023 2022 Balances from contracts with customers only: Accounts receivable $ 120,304 $ 116,247 Deferred revenue (included in accrued liabilities and $ 14,605 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 13,808 $ 13,390 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets Goodwill The following table represents the change in the carrying value of goodwill for the six months ended June 30, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Acquisition of FlexBiosys, Inc. 14,355 Cumulative translation adjustment 820 Balance at June 30, 2023 $ 870,688 During each of the fourth quarters of 2022, 2021 and 2020, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and six months ended June 30, 2023. Intangible Assets Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. Intangible assets, net, consisted of the following at June 30, 2023: June 30, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 200,468 $ ( 37,053 ) $ 163,415 16 Patents 240 ( 240 ) — 8 Customer relationships 255,546 ( 74,896 ) 180,650 16 Trademarks 7,717 ( 1,544 ) 6,173 19 Other intangibles 3,039 ( 2,273 ) 766 4 Total finite-lived intangible assets 467,010 ( 116,006 ) 351,004 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 467,710 $ ( 116,006 ) $ 351,704 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,463 $ ( 30,992 ) $ 159,471 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 454,130 ( 101,154 ) 352,976 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 454,830 $ ( 101,154 ) $ 353,676 Amortization expense for finite-lived intangible assets was $ 7.5 million and $ 6.6 million for each of the three months ended June 30, 2023 and 2022, respectively, and $ 14.9 million and $ 13.2 million for each of the six months ended June 30, 2023 and 2022 , respectively. As of June 30, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2023 (remaining six months) $ 15,031 2024 29,599 2025 29,369 2026 29,195 2027 29,161 2028 and thereafter 218,649 Total $ 351,004

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	6 Months Ended
	Jun. 30, 2023
Disclosure Text Block [Abstract]
Consolidated Balance Sheet Detail	6. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 147,996 $ 149,438 Work-in-process 4,811 6,183 Finished products 88,062 82,656 Total inventories, net $ 240,869 $ 238,277 Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Land $ 976 $ 1,003 Buildings 1,657 1,599 Leasehold improvements 124,277 115,672 Equipment 110,047 94,613 Furniture, fixtures and office equipment 8,652 8,307 Computer hardware and software 34,314 29,813 Construction in progress 31,082 31,553 Other 467 420 Total property, plant and equipment 311,472 282,980 Less - Accumulated depreciation ( 108,908 ) ( 92,307 ) Total property, plant and equipment, net $ 202,564 $ 190,673 Accrued Liabilities Accrued liabilities consist of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Employee compensation $ 11,645 $ 33,522 Deferred revenue 13,987 19,283 Income taxes payable 4,700 2,459 Other 14,691 15,856 Total accrued liabilities $ 45,023 $ 71,120

Convertible Senior Notes

Convertible Senior Notes	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Convertible Senior Notes	7. Convertible Senior Notes 0.375% Convertible Senior Notes due 2024 On July 19, 2019, the Company issued $ 287.5 million aggregate principal pursuant to the 2019 Notes, which includes the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375 % per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2019 Notes will mature on July 15, 2024 , unless earlier repurchased or converted in accordance with their terms. During the second quarter of 2023, the closing price of the Company’s common stock exceeded 130 % of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2019 Notes are convertible at the option of the holders of the 2019 Notes during the third quarter of 2023, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. These conditions have been met each quarter since the third quarter of 2020. As a result, $ 0.1 million aggregate principal amount of the 2019 Notes have been requested for conversion by the note holders since the issuance of the 2019 Notes and all conversions have settled as of June 30, 2023 except $ 24,000 aggregate principal amount, which settles in the third quarter of 2023. The conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. The Company continues to classify the carrying value of the 2019 Notes as current liabilities on the Company’s condensed consolidated balance sheets at June 30, 2023. The net carrying value of the liability component of the 2019 Notes is as follows: June 30, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,461 $ 287,470 Unamortized debt issuance costs ( 1,940 ) ( 2,855 ) Net carrying amount $ 285,521 $ 284,615 The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Contractual interest expense $ 269 $ 269 $ 539 $ 539 Amortization of debt issuance costs 457 453 914 905 Total $ 726 $ 722 $ 1,453 $ 1,444 Effective interest rate of the liability component 1 % 1 % 1 % 1 % At June 30, 2023 and December 31, 2022, the carrying value of the 2019 Notes was $ 285.5 million and $ 284.6 million, respectively, net of unamortized discount, and the fair value of the 2019 Notes was $ 372.8 million and $ 452.0 million, respectively. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at June 30, 2023 and December 31, 2022 .

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Stock Option and Incentive Plans Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that were reserved and available for issuance is 2,778,000 , plus the number of shares of common stock that were available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At June 30, 2023, 1,717,510 shares were available for future grants under the 2018 Plan. Stock Issued for Earnout Payment In May 2023, the Company issued 42,621 shares of its common stock to former securityholders of Avitide to satisfy the contingent consideration obligation established under the Agreement and Plan of Merger and Reorganization (the "Avitide Agreement") which the Company entered into as part of the acquisition of Avitide in September 2021. See Note 4, "Acquisitions", included in Part II, Item 8 "Financial Statements and Supplemental Data" to our Form 10-K, for additional information on the acquisition of Avitide and the contingent consideration. The shares represent 50 % of the earnout consideration earned in the First Earnout Year (as defined in the Avitide Agreement). Stock-Based Compensation The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Cost of product revenue $ 522 $ 615 $ 1,113 $ 1,237 Research and development 608 622 1,395 1,421 Selling, general and administrative 4,353 5,748 10,229 12,242 Total stock-based compensation $ 5,483 $ 6,985 $ 12,737 $ 14,900 Stock Options Information regarding option activity for the six months ended June 30, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 55,545 $ 175.75 Exercised ( 4,650 ) $ 13.30 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at June 30, 2023 658,860 $ 80.53 Options exercisable at June 30, 2023 387,604 $ 58.94 Vested and expected to vest at June 30, 2023 (1) 644,427 $ 80.08 5.77 $ 47,205 (1) Represents the number of vested options as of June 30, 2023 plus the number of unvested options expected to vest as of June 30, 2023 based on the unvested outstanding options at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on June 30, 2023, the last business day of the first quarter of 2023, of $ 141.46 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on June 30, 2023. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $ 0.7 million and $ 2.4 million, respectively. The weighted average grant date fair value of options granted during the six months ended June 30, 2023 and 2022 was $ 86.30 and $ 76.64 , respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the six months ended June 30, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 158,084 $ 176.86 Vested ( 156,784 ) $ 115.85 Forfeited/cancelled ( 39,397 ) $ 182.56 Unvested at June 30, 2023 492,937 $ 157.94 Vested and expected to vest at June 30, 2023 (1) 432,340 $ 154.21 (1) Represents the number of vested stock units as of June 30, 2023 plus the number of unvested stock units expected to vest as of June 30, 2023 based on the unvested outstanding stock units at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value of stock units vested during the six months ended June 30, 2023 and 2022 was $ 29.6 million and $ 37.5 million, respectively. The weighted average grant date fair value of stock units granted during the six months ended June 30, 2023 and 2022 was $ 176.86 and $ 191.09 , respectively. As of June 30, 2023, there was $ 73.2 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.93 years. The Company expects 2,154,003 unvested options and stock units to vest over the next five years .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Collaboration Agreements The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and six months ended June 30, 2023 and 2022. In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $ 1.2 million and $ 0.7 million for the three months ended June 30, 2023 and 2022 , respectively, and payments of $ 2.3 million and $ 1.1 million for the six months ended June 30, 2023 and 2022, respectively. Legal Proceedings From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company's view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probably that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial results.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes For the three and six months ended June 30, 2023, the Company recorded an income tax provision of $ 5.1 million and $ 12.4 million, respectively. The Company’s effective tax rate for the three and six months ended June 30, 2023 was 20.3 % and 20.2 % , respectively, compared to 16.6 % and 18.4 % for the corresponding periods in the prior year. The difference in effective tax rates between the periods was primarily due to lower income before taxes and increased benefits from business tax credits partially offset by nondeductible contingent consideration and lower foreign-derived intangible income. On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022 ("Inflation Reduction Act"), which, among other things, implements a 15 % alternative minimum tax on global adjusted financial statement income of certain large corporations, a 1 % excise tax on net stock repurchases and several tax incentives to promote clean energy and was effective beginning in 2023. We evaluated the provisions of the Inflation Reduction Act and no provision had a material effect on our consolidated financial position or results of operations.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share, Basic [Abstract]
Earnings Per Share	11. Earnings Per Share A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands, except per share data) Numerator: Net income $ 20,064 $ 49,861 $ 48,893 $ 96,825 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — — 387 Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities $ 20,064 $ 49,861 $ 48,893 $ 97,212 Denominator: Weighted average shares used in computing net income per share - basic 55,705 55,444 55,648 55,399 Effect of dilutive shares: Options and stock units 451 598 487 661 Convertible Senior Notes 701 676 797 1,779 Dilutive effect of unvested performance stock units 1 3 1 3 Dilutive potential common shares 1,153 1,277 1,284 2,443 Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted 56,858 56,721 56,932 57,842 Earnings per share: Basic $ 0.36 $ 0.90 $ 0.88 $ 1.75 Diluted $ 0.35 $ 0.88 $ 0.86 $ 1.68 For the three and six months ended June 30, 2023, 456,315 shares and 400,909 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted EPS because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. Comparatively, for the three and six months ended June 30, 2022, 325,685 shares and 306,400 shares, respectively, were considered anti-dilutive. In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, prior to March 4, 2022, conversion of the 2019 Notes could have been settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. On March 4, 2022, we entered into the Second Supplemental Indenture for the 2019 Notes, which irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and shares of the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company adopted ASU 2020-06 effective January 1, 2022. Under ASU 2020-06, the Company is required to reflect the dilutive effect of the convertible securities by application of the "if-converted" method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Prior to March 4, 2022, the Company had the choice to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the EPS calculation, applying the if converted method. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock, and from March 5, 2022 forward, only the excess premium will be settled with shares. Under the if-converted method of calculating dilutive shares, the Company was also required to exclude amortization of debt issuance costs and interest charges applicable to the convertible debt from the numerator of the dilutive EPS calculation for the period from January 1, 2022 to March 4, 2022, as if the interest on convertible debt was never recognized for that period. For the three months ended March 31, 2022, the Company excluded interest charges of $ 0.4 million (net of tax) from the numerator. Prior to the adoption of ASU 2020-06, the Company applied the provisions of ASC 260, “Earnings Per Share,” Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it related to the conversion spread on its convertible notes. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. Pursuant to this accounting standard, there was no dilution from the accreted principal of the 2019 Notes. For the three and six months ended June 30, 2023, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 700,941 shares and 796,601 shares, respectively. For the three and six months ended June 30, 2022, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 676,166 shares and 1,779,041 shares, respectively.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions Certain facilities leased by Spectrum are owned by the Roy T. Eddleman Living Trust (the "Trust"). As of June 30, 2023 , the Trust owned greater than 5 % of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust prior to the public offering were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense totaling $ 0.2 million for each of the three months ended June 30, 2023 and 2022 related to these leases and incurred rent expense of $ 0.4 million for each of the six months ended June 30, 2023 and 2022 .

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	13. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Revenue by customers' geographic locations: North America 46 % 45 % 42 % 43 % Europe 36 % 35 % 37 % 39 % APAC/Other 18 % 20 % 21 % 18 % Total revenue 100 % 100 % 100 % 100 % Concentrations of Credit Risk and Significant Customers Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At June 30, 2023 and December 31, 2022, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the three and six months ended June 30, 2023 and 2022. Significant accounts receivable balances representing 10 % or more of the Company’s total trade accounts receivable and royalties at June 30, 2023 and December 31, 2022 came from our accounts receivable balance outstanding with Purolite, an Ecolab Inc. company, which was 11.5 % and 12.7 %, respectively, of our total accounts receivable and other receivable balance.

Restructuring Plan

Restructuring Plan	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Plan	14. Restructuring Plan In July 2023, we announced that the Board of Directors has authorized our management team to undertake restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. As part of these efforts, we expect to incur approximately $ 6 million in restructuring charges in the second half of the year, as a result of severance costs.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Ltd., ARTeSYN Biosolutions Ireland Limited and its subsidiaries ("ARTeSYN"), Polymem S.A. (“Polymem”), Avitide LLC ("Avitide"), Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex"), Repligen Singapore Pte. Ltd., Repligen UK Limited and FlexBiosys, Inc. ("FlexBiosys"). All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes, which the Company adopted effective January 1, 2022 as required by Accounting Standards Update No. ("ASU" or "ASUs") 2020-06 and discussed in Note 6, "Convertible Senior Notes," to these condensed consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the three and six months ended June 30, 2023 and 2022 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Recent Accounting Standards Updates	Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s condensed consolidated financial statements. As of June 30, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Marketable Securities Held to Maturity	The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of June 30, 2023 and December 31, 2022 (amounts in thousands): As of June 30, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 603,656 $ — $ — $ 603,656 Total cash and cash equivalents $ 603,656 $ — $ — $ 603,656 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills - short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781
Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity	The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 is summarized below: December 31, 2022 Amortized Estimated Maturity of one year or less $ 100,299 $ 100,323 Total $ 100,299 $ 100,323
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2023 and December 31, 2022 (amounts in thousands): As of June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 433,966 $ — $ — $ 433,966 Liabilities: Short-term contingent consideration $ — $ — $ 16,363 $ 16,363 Long-term contingent consideration $ — $ — $ 44,277 $ 44,277 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559
Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout	A reconciliation of the change in the fair value of contingent consideration - earnouts is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Acquisition date fair value of contingent consideration earnout 6,632 Payment of contingent consideration earnout ( 14,527 ) Decrease in fair value of contingent consideration earnouts 3,026 Balance at June 30, 2023 $ 60,640
Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs	The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023, 2024 and 2025 contingent consideration obligations for Avitide and FlexBiosys include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 19,175 Monte Carlo Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Volatility 22.5 %- 24.6 % 23.6 % Revenue and Volume- $ 35,960 Monte Carlo Revenue & Volume 5.7 %- 9.3 % 7.5 % Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Probability of 100 % 100 % Manufacturing line expansions $ 5,505 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisition of FlexBiosys, Inc

Acquisition of FlexBiosys, Inc (Tables) - FlexBiosys, Inc.	6 Months Ended
	Jun. 30, 2023
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 9,530 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,355 Other long-term assets 2,514 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Operating lease liability, long-term ( 3,498 ) Fair value of net assets acquired $ 41,064
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenues for the three and six months ended June 30, 2023 and 2022 were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Product revenue $ 159,133 $ 207,597 $ 341,754 $ 413,960 Royalty and other income 36 36 75 73 Total revenue $ 159,169 $ 207,633 $ 341,829 $ 414,033
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2023 (amounts in thousands): June 30, December 31, 2023 2022 Balances from contracts with customers only: Accounts receivable $ 120,304 $ 116,247 Deferred revenue (included in accrued liabilities and $ 14,605 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 13,808 $ 13,390

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Changes in Carrying Value of Goodwill	The following table represents the change in the carrying value of goodwill for the six months ended June 30, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Acquisition of FlexBiosys, Inc. 14,355 Cumulative translation adjustment 820 Balance at June 30, 2023 $ 870,688
Schedule of Intangible Assets	Intangible assets, net, consisted of the following at June 30, 2023: June 30, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 200,468 $ ( 37,053 ) $ 163,415 16 Patents 240 ( 240 ) — 8 Customer relationships 255,546 ( 74,896 ) 180,650 16 Trademarks 7,717 ( 1,544 ) 6,173 19 Other intangibles 3,039 ( 2,273 ) 766 4 Total finite-lived intangible assets 467,010 ( 116,006 ) 351,004 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 467,710 $ ( 116,006 ) $ 351,704 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,463 $ ( 30,992 ) $ 159,471 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 454,130 ( 101,154 ) 352,976 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 454,830 $ ( 101,154 ) $ 353,676
Schedule of Amortization Expense for Amortized Intangible Assets	As of June 30, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2023 (remaining six months) $ 15,031 2024 29,599 2025 29,369 2026 29,195 2027 29,161 2028 and thereafter 218,649 Total $ 351,004

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure Text Block [Abstract]
Inventories	Inventories, net Inventories, net consists of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 147,996 $ 149,438 Work-in-process 4,811 6,183 Finished products 88,062 82,656 Total inventories, net $ 240,869 $ 238,277
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Land $ 976 $ 1,003 Buildings 1,657 1,599 Leasehold improvements 124,277 115,672 Equipment 110,047 94,613 Furniture, fixtures and office equipment 8,652 8,307 Computer hardware and software 34,314 29,813 Construction in progress 31,082 31,553 Other 467 420 Total property, plant and equipment 311,472 282,980 Less - Accumulated depreciation ( 108,908 ) ( 92,307 ) Total property, plant and equipment, net $ 202,564 $ 190,673
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following: June 30, December 31, 2023 2022 (Amounts in thousands) Employee compensation $ 11,645 $ 33,522 Deferred revenue 13,987 19,283 Income taxes payable 4,700 2,459 Other 14,691 15,856 Total accrued liabilities $ 45,023 $ 71,120

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Carrying Value of Convertible Senior Notes	The net carrying value of the liability component of the 2019 Notes is as follows: June 30, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,461 $ 287,470 Unamortized debt issuance costs ( 1,940 ) ( 2,855 ) Net carrying amount $ 285,521 $ 284,615
Schedule of convertiable note interest expense	The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Contractual interest expense $ 269 $ 269 $ 539 $ 539 Amortization of debt issuance costs 457 453 914 905 Total $ 726 $ 722 $ 1,453 $ 1,444 Effective interest rate of the liability component 1 % 1 % 1 % 1 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stock-Based Compensation Expense	The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands) Cost of product revenue $ 522 $ 615 $ 1,113 $ 1,237 Research and development 608 622 1,395 1,421 Selling, general and administrative 4,353 5,748 10,229 12,242 Total stock-based compensation $ 5,483 $ 6,985 $ 12,737 $ 14,900
Summary of Option Activity	Information regarding option activity for the six months ended June 30, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 55,545 $ 175.75 Exercised ( 4,650 ) $ 13.30 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at June 30, 2023 658,860 $ 80.53 Options exercisable at June 30, 2023 387,604 $ 58.94 Vested and expected to vest at June 30, 2023 (1) 644,427 $ 80.08 5.77 $ 47,205 (1) Represents the number of vested options as of June 30, 2023 plus the number of unvested options expected to vest as of June 30, 2023 based on the unvested outstanding options at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.
Summary of Restricted Stock Unit Activity	Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the six months ended June 30, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 158,084 $ 176.86 Vested ( 156,784 ) $ 115.85 Forfeited/cancelled ( 39,397 ) $ 182.56 Unvested at June 30, 2023 492,937 $ 157.94 Vested and expected to vest at June 30, 2023 (1) 432,340 $ 154.21 Represents the number of vested stock units as of June 30, 2023 plus the number of unvested stock units expected to vest as of June 30, 2023 based on the unvested outstanding stock units at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share, Basic [Abstract]
Basic and Diluted Weighted Average Shares Outstanding	A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Amounts in thousands, except per share data) Numerator: Net income $ 20,064 $ 49,861 $ 48,893 $ 96,825 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — — 387 Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities $ 20,064 $ 49,861 $ 48,893 $ 97,212 Denominator: Weighted average shares used in computing net income per share - basic 55,705 55,444 55,648 55,399 Effect of dilutive shares: Options and stock units 451 598 487 661 Convertible Senior Notes 701 676 797 1,779 Dilutive effect of unvested performance stock units 1 3 1 3 Dilutive potential common shares 1,153 1,277 1,284 2,443 Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted 56,858 56,721 56,932 57,842 Earnings per share: Basic $ 0.36 $ 0.90 $ 0.88 $ 1.75 Diluted $ 0.35 $ 0.88 $ 0.86 $ 1.68

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2023
Text Block [Abstract]
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Revenue by customers' geographic locations: North America 46 % 45 % 42 % 43 % Europe 36 % 35 % 37 % 39 % APAC/Other 18 % 20 % 21 % 18 % Total revenue 100 % 100 % 100 % 100 %

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Company's Cash, Cash Equivalents and Marketable Securities Held to Maturity (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash and money market funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs		$ 523,458
Cash and cash equivalents, Estimated Fair Value		523,458
Cash and cash equivalents
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs	$ 603,656	523,458
Cash and cash equivalents, Estimated Fair Value	$ 603,656	523,458
U.S. treasury bills
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs		100,299
Marketable securities, Gross Unrealized Gains		24
Marketable securities, Estimated Fair Value		100,323
Cash equivalents and marketable securities
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs		623,757
Marketable securities, Gross Unrealized Gains		24
Marketable securities, Estimated Fair Value		$ 623,781

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Fair Value Disclosures [Abstract]
Debt Securities Maturity Within One Year Amortized Cost	$ 100,299
Maturity of one year or less, Estimated Fair Value	$ 100,323

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	$ 16,363	$ 13,950
Long-term contingent consideration	44,277	51,559
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	433,966	343,929
Level 1 | Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	433,966	343,929
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	16,363	13,950
Long-term contingent consideration	$ 44,277	$ 51,559

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
	Apr. 17, 2023	Dec. 31, 2022	Jun. 30, 2023
Summary Of Significant Accounting Policies [Line Items]
Purchase of treasury stock		$ 100
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration			$ 125
FlexBiosys, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration	$ 6.6		$ 42

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment of contingent consideration earnout	$ 1,791	$ (6,884)	$ 3,026	$ (9,295)
Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of December 31, 2022			65,509
Acquisition date fair value of contingent consideration earnout			6,632
Payment of contingent consideration earnout			(14,527)
Decrease in fair value of contingent consideration earnouts			(3,026)
Balance as of June 30 , 2023	$ 60,640		$ 60,640

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 60,640	$ 65,509
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 35,960
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	23.60%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	7.50%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 5,505
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Volatility		22.50%
Revenue and volume discount rate		5.70%
Minimum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
Volatility		24.60%
Revenue and volume discount rate		9.30%
Maximum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 19,175
Probability of success		100%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Avitide and FlexBiosys | Minimum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Avitide and FlexBiosys | Maximum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisition of FlexBiosys, In_2

Acquisition of FlexBiosys, Inc - Additional Information (Detail) - USD ($) $ in Thousands		6 Months Ended
	Apr. 17, 2023	Jun. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 870,688	$ 855,513
FlexBiosys, Inc.
Business Acquisition [Line Items]
Business combination date of acquistion	Apr. 17, 2023
Equity consideration	$ 41,100
Cash consideration	29,000
Business Combination, Indemnification Assets, Range of Outcomes, Value, High	$ 6,300
Shares of common stock issued for acquisition	31,415	31,415
Value of common stock issued	$ 41,100
Business combination contingent consideration	6,600	$ 42,000
Net liabilities assumed	14,100
Business combination, intangible assets	12,600
Intangible Asset Residual Value	14,400
Transaction costs		400
Goodwill		$ 14,355
FlexBiosys, Inc. | Common Stock
Business Acquisition [Line Items]
Equity consideration	5,400
Value of common stock issued	$ 5,400

Acquisition of FlexBiosys, In_3

Acquisition of FlexBiosys, Inc - Fair Value of Net Assets Acquired (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Apr. 17, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 870,688		$ 855,513
FlexBiosys, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents	1,090
Accounts receivable	683
Inventory	667
Prepaid expenses and other current assets	35
Property and equipment	9,530
Operating lease right of use asset	3,537
Business combination, intangible assets		$ 12,600
Goodwill	14,355
Other long-term assets	2,514
Accounts payable	(136)
Accrued liabilities	(314)
Operating lease liability	(39)
Operating lease liability, long-term	(3,498)
Fair value of net assets acquired	41,064
FlexBiosys, Inc. | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	2,530
FlexBiosys, Inc. | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	9,860
FlexBiosys, Inc. | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	30
FlexBiosys, Inc. | Non-compete agreements
Business Acquisition [Line Items]
Business combination, intangible assets	$ 220

Acquisitionsof FlexBiosys, Inc

Acquisitionsof FlexBiosys, Inc - Estimated Useful Life and Fair Value (Detail) - FlexBiosys, Inc. $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Fair Value	$ 12,640
Customer relationships
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	12 years
Fair Value	$ 2,530
Developed technology
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	16 years
Fair Value	$ 9,860
Trademark and tradename
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	4 years
Fair Value	$ 30
Non-compete agreements
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	5 years
Fair Value	$ 220

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 159,169	$ 207,633	$ 341,829	$ 414,033
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	159,133	207,597	341,754	413,960
Royalty and Other Income
Disaggregation of Revenue [Line Items]
Total revenue	$ 36	$ 36	$ 75	$ 73

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Balances from contracts with customers only:
Accounts receivable	$ 120,304	$ 116,247
Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets)	14,605	19,631
Revenue recognized during periods presented relating to:
The beginning deferred revenue balance	$ 13,808	$ 13,390

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Value of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Line Items]
Balance	$ 855,513
Acquisition of FlexBiosys, Inc	14,355
Cumulative translation adjustment	820
Balance	$ 870,688

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Liabilities [Line Items]
Impairment of intangible assets			$ 0
Amortization of Intangible Assets	$ 7.5	$ 6.6	$ 14.9	$ 13.2

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 467,010	$ 454,130
Gross Carrying Value	467,710	454,830
Accumulated Amortization	(116,006)	(101,154)
Accumulated Amortization	(116,006)	(101,154)
Net Carrying Value	351,004	352,976
Net Carrying Value	$ 351,704	$ 353,676
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	200,468	190,463
Accumulated Amortization	(37,053)	(30,992)
Net Carrying Value	$ 163,415	$ 159,471
Weighted Average Useful Life (in years)	16 years	16 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	(240)	(240)
Net Carrying Value	$ 0	$ 0
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 255,546	$ 252,934
Accumulated Amortization	(74,896)	(66,559)
Net Carrying Value	$ 180,650	$ 186,375
Weighted Average Useful Life (in years)	16 years	15 years
Trademarks
Intangible Assets [Line Items]
Gross Carrying Value	$ 7,717	$ 7,682
Accumulated Amortization	(1,544)	(1,319)
Net Carrying Value	$ 6,173	$ 6,363
Weighted Average Useful Life (in years)	19 years	19 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 3,039	$ 2,811
Accumulated Amortization	(2,273)	(2,044)
Net Carrying Value	$ 766	$ 767
Weighted Average Useful Life (in years)	4 years	4 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Liabilities [Line Items]
2023 (remaining six months)	$ 15,031
2024	29,599
2025	29,369
2026	29,195
2027	29,161
2028 and thereafter	218,649
Total	$ 351,004	$ 352,976

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 147,996	$ 149,438
Work-in-process	4,811	6,183
Finished products	88,062	82,656
Total inventories, net	$ 240,869	$ 238,277

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Land	$ 976	$ 1,003
Buildings	1,657	1,599
Leasehold improvements	124,277	115,672
Equipment	110,047	94,613
Furniture, fixtures and office equipment	8,652	8,307
Computer hardware and software	34,314	29,813
Construction in progress	31,082	31,553
Other	467	420
Total property, plant and equipment	311,472	282,980
Less - Accumulated depreciation	(108,908)	(92,307)
Total property, plant and equipment, net	$ 202,564	$ 190,673

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 11,645	$ 33,522
Deferred revenue	13,987	19,283
Income taxes payable	4,700	2,459
Other	14,691	15,856
Total accrued liabilities	$ 45,023	$ 71,120

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail)		6 Months Ended
	Jul. 19, 2019 USD ($)	Jun. 30, 2023 USD ($) Days	Dec. 31, 2022 USD ($)	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Trading Days | Days		20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | Days		30
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Notes issued	$ 287,500,000			$ 287,500,000
Notes, interest rate	0.375%
Proceeds from issuance of convertible senior notes, net of costs	$ 278,500,000
Interest repayment terms		Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.
Notes, due date		Jul. 15, 2024
Notes, carrying value		$ 285,500,000	$ 284,600,000
Fair value of the note		372,800,000	$ 452,000,000
Additional Notes issued	$ 37,500,000
Debt instrument amount convertible into equity		$ 100,000
Notes threshold percentage of stock price trigger		130%
Debt instrument convertible into equity not yet converted		$ 24,000

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total convertible senior notes	$ 285,521	$ 284,615
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Principal amount	287,461	287,470
Unamortized debt issuance costs	(1,940)	(2,855)
Total convertible senior notes	285,500	284,600
Total convertible senior notes	$ 285,521	$ 284,615

Convertible Senior Notes - Sche

Convertible Senior Notes - Schedule of convertiable note interest expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Contractual interest expense	$ 269	$ 269	$ 539	$ 539
Amortization of debt issuance costs	457	453	914	905
Total	$ 726	$ 722	$ 1,453	$ 1,444
Debt Instrument, Interest Rate, Effective Percentage	1%	1%	1%	1%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	May 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of stock options exercised	$ 0.7	$ 2.4
Weighted average grant date fair value of share-based awards granted	$ 86.3	$ 76.64
Weighted average grant date fair value of restricted stock units granted	$ 176.86
Total unrecognized compensation cost	$ 73.2
Unrecognized compensation cost, weighted average remaining requisite service period	2 years 11 months 4 days
Number of unvested options and restricted stock units	2,154,003
Common stock, shares issued	55,744,896				55,557,698
Avitide LLC
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued			42,621
Earnout consideration earned			50%
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance						2,778,000
Incentive options, vesting period	1,717,510
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period	5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested	$ 29.6	$ 37.5
Weighted average grant date fair value of restricted stock units granted	$ 176.86	$ 191.09
RestrictedStockUnitsRSUMember
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock				$ 141.46

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 5,483	$ 6,985	$ 12,737	$ 14,900
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	522	615	1,113	1,237
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	608	622	1,395	1,421
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 4,353	$ 5,748	$ 10,229	$ 12,242

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Options Outstanding
Options outstanding at December 31, 2021| shares | shares	609,965
Granted | shares | shares	55,545
Exercised | shares | shares	(4,650)
Forfeited/expired/cancelled | shares	(2,000)
Options outstanding at September 30, 2022 | shares | shares	658,860
Options exercisable at September 30, 2022 | shares | shares	387,604
Vested and expected to vest at September 30, 2022 (1) | shares | shares	644,427	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2021 | $ / shares	$ 71.74
Granted | $ / shares	175.75
Exercised | $ / shares	13.3
Forfeited/expired/cancelled | $ / shares	199.71
Options outstanding at September 30, 2022 | $ / shares	80.53
Options exercisable at September 30, 2022 | $ / shares	58.94
Vested and expected to vest at March 31, 2023 | $ / shares	$ 80.08	[1]
Weighted-Average Remaining Contractual Term (in years)
Vested and expected to vest at September 30, 2022	5 years 9 months 7 days	[1]
Aggregate Intrinsic Value
Vested and expected to vest at September 30, 2022 | $	$ 47,205	[1]
[1] Represents the number of vested options as of June 30, 2023 plus the number of unvested options expected to vest as of June 30, 2023 based on the unvested outstanding options at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Jun. 30, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Options Outstanding
Unvested at December 31, 2022 | shares	531,034
Awarded | shares	158,084
Vested | shares	(156,784)
Forfeited/expired/cancelled | shares	(39,397)
Unvested at March 31, 2023 | shares	492,937
Vested and expected to vest at March 31, 2023 | shares	432,340	[1]
Weighted-Average Remaining Contractual Term (in years)
Weighted Average, Unvested at December 31,2022 | $ / shares	$ 142.57
Weighted Average, Awarded | $ / shares	176.86
Weighted Average, Vested | $ / shares	115.85
Weighted Average, Forfeited/Cancelled | $ / shares	182.56
Weighted Average, Unvested at March 31, 2023 | $ / shares	157.94
Weighted Average, Vested and expected to vest at March 31, 2023 | $ / shares	$ 154.21	[1]
[1] Represents the number of vested stock units as of June 30, 2023 plus the number of unvested stock units expected to vest as of June 30, 2023 based on the unvested outstanding stock units at June 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units and Performance Stock Units	Jun. 30, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
NGL Impact A [Member] | Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Royalty payments	$ 1.2	$ 0.7	$ 2.3	$ 1.1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Aug. 16, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Taxes [Line Items]
Income tax provision		$ 5,096	$ 9,895	$ 12,359	$ 21,862
Income tax (benefit) provision		20.30%	16.60%	20.20%	18.40%
Inflation Reduction Act Of Two Thousand Twenty Two [Member]
Income Taxes [Line Items]
Percentage of alternative minimum tax	15%
Percent of excise tax on net stock repurchases	1%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
	Mar. 04, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jul. 31, 2019	Jul. 19, 2019
Stock options, outstanding		658,860			658,860		609,965
Stock options, weighted average exercise price		$ 80.53			$ 80.53		$ 71.74
Restricted stock units, outstanding		492,937			492,937		531,034
Common stock excluded from calculation of diluted earnings per share		456,315	325,685		400,909	306,400
Dilutive effect on shares of conversion premium		700,941	676,166		796,601	1,779,041
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted		56,858	56,721		56,932	57,842
Charges associated with convertible debt instruments, net of tax		$ 0	$ 0		$ 0	$ 387
AccountingStandardsUpdate202006Member
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	3,474,429
Charges associated with convertible debt instruments, net of tax				$ 400
0.375% Convertible Senior Notes due 2024
Principal amount								$ 287,500	$ 287,500

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic and Diluted Shares Amounts (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator
Net Income (Loss)	$ 20,064	$ 49,861	$ 48,893	$ 96,825
Effect of dilutive securities
Charges associated with convertible debt instruments, net of tax	0	0	0	387
Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities	$ 20,064	$ 49,861	$ 48,893	$ 97,212
Denominator
Weighted average shares used in computing net income per share - basic	55,705	55,444	55,648	55,399
Effect of dilutive shares
Options and stock units	451	598	487	661
Convertible Senior Notes	701	676	797	1,779
Dilutive effect of unvested performance stock units	1	3	1	3
Dilutive potential common shares	1,153	1,277	1,284	2,443
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	56,858	56,721	56,932	57,842
Earnings per share:
Basic	$ 0.36	$ 0.9	$ 0.88	$ 1.75
Diluted (Note 11)	$ 0.35	$ 0.88	$ 0.86	$ 1.68

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Principal Owner - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Line Items]
Rental expense	$ 0.2	$ 0.2	$ 0.4	$ 0.4
Minimum | Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5%		5%

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Segment	Jun. 30, 2022 USD ($)	Dec. 31, 2022
Number of operating segments | Segment			1
Accounts receivable, percentage by customer	100%	100%	100%	100%
Revenue	$ 159,169	$ 207,633	$ 341,829	$ 414,033
Sales Revenue
Revenue	$ 0	$ 0	$ 0	$ 0
Customer Concentration Risk | Accounts Receivable [Member] | Purolite [Member]
Accounts receivable, percentage by customer			11.50%		12.70%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Purolite [Member]
Accounts receivable, percentage by customer			10%		10%
Customer Concentration Risk | Minimum [Member] | Sales Revenue
Accounts receivable, percentage by customer	10%	10%	10%	10%

Segment Reporting - Percentage

Segment Reporting - Percentage of Revenue by Geographic Area (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Revenues, percentage by country	100%	100%	100%	100%
Geographic Concentration Risk | Total Revenue | North America
Concentration Risk [Line Items]
Revenues, percentage by country	46%	45%	42%	43%
Geographic Concentration Risk | Total Revenue | Europe
Concentration Risk [Line Items]
Revenues, percentage by country	36%	35%	37%	39%
Geographic Concentration Risk | Total Revenue | APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	18%	20%	21%	18%

Restructuring Plan - Additional

Restructuring Plan - Additional Information (Detail) $ in Millions	1 Months Ended
	Jul. 31, 2023 USD ($)
Subsequent Event | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 6